Financial Payments to Teaching Hospitals by Companies Marketing Opioids
J Gen Intern Med
.
2020 Oct;35(10):3108-3110.
doi: 10.1007/s11606-019-05596-1.
Epub 2019 Dec 17.
Authors
Timothy S Anderson
1
,
Maxwell S Krieger
2
,
Brandon D L Marshall
2
,
Magdalena Cerdá
3
4
,
Scott Hadland
5
6
7
Affiliations
1
Division of General Medicine, Beth Israel Deaconess Medical Center, 1309 Beacon Street, Brookline, MA, 02446, USA. tsander1@bidmc.harvard.edu.
2
Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA.
3
Department of Population Health, New York University School of Medicine, New York, USA.
4
Center for Opioid Epidemiology and Policy, New York University School of Medicine, New York, USA.
5
Grayken Center for Addiction, Boston Medical Center, Boston, MA, USA.
6
Department of Pediatrics, Boston Medical Center, Boston, MA, USA.
7
Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, Boston, MA, USA.
PMID:
31848860
PMCID:
PMC7572903
DOI:
10.1007/s11606-019-05596-1
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Analgesics, Opioid*
Conflict of Interest
Hospitals, Teaching
Humans
Marketing*
United States
Substances
Analgesics, Opioid
Grants and funding
K23 DA045085/DA/NIDA NIH HHS/United States
P20 GM125507/GM/NIGMS NIH HHS/United States
K08DA045085/DA/NIDA NIH HHS/United States
P20-GM125507/GM/NIGMS NIH HHS/United States